Timothy Akhurst
YOU?
Author Swipe
View article: The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (<sup>18</sup>F) positron‐emission tomography positive intermediate grade pancreatic neuroendocrine tumors
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (<sup>18</sup>F) positron‐emission tomography positive intermediate grade pancreatic neuroendocrine tumors Open
Aims This multicenter phase II trial evaluates the efficacy of everolimus in poor prognosis grade 2 (G2) pancreatic neuroendocrine tumors (PNETs), defined by 2‐[fluorine‐18]fluoro‐2‐deoxy‐d‐glucose (FDG) positron‐emission tomography (PET) …
View article: First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers Open
Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimize pharmacokinetics and bioavailability to tumor. We report the preclinica…